Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
19.80
-0.59 (-2.89%)
May 6, 2025, 4:00 PM EDT - Market closed
Enliven Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Enliven Therapeutics stock have an average target of 39.25, with a low estimate of 36 and a high estimate of 42. The average target predicts an increase of 98.23% from the current stock price of 19.80.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 21, 2025.
Analyst Ratings
The average analyst rating for Enliven Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $37 → $39 | Strong Buy | Maintains | $37 → $39 | +96.97% | Mar 21, 2025 |
| BTIG | BTIG | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | +112.12% | Dec 13, 2024 |
| Baird | Baird | Buy Maintains $32 → $40 | Buy | Maintains | $32 → $40 | +102.02% | Nov 15, 2024 |
| Jones Trading | Jones Trading | Strong Buy Initiates $36 | Strong Buy | Initiates | $36 | +81.82% | Oct 31, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $37 | Strong Buy | Reiterates | $37 | +86.87% | Oct 1, 2024 |
Financial Forecast
Revenue This Year
n/a
from 72.89M
Revenue Next Year
n/a
EPS This Year
-2.26
from -1.89
EPS Next Year
-2.66
from -2.26
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 52,500 | 52,500 | 52,500 | ||
| Avg | 10,200 | 10,200 | 12,750 | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -99.9% | 414.7% | 414.7% | ||
| Avg | -100.0% | - | 25.0% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.98 | -1.86 | -1.79 |
| Avg | -2.26 | -2.66 | -3.17 |
| Low | -2.49 | -3.83 | -4.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.